Sarah B. Noonberg's Insider Trades & SAST Disclosures
Sarah B. Noonberg's most recent trade in Metagenomi Inc. was a trade of 84,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sarah B. Noonberg.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Metagenomi Inc. | Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Metagenomi Inc. | Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 14,000 | 114,374 | - | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 10,450 | 10,450 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 2,300 | 14,100 (0%) | 0% | 0 | Common Stock | |
| Neurogene Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 7,700 | 7,700 | - | - | Stock Option (Right to Buy) | |
| Metagenomi Inc. | Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 242,875 | 242,875 | - | - | Stock Option (Right to Buy) | |
| Metagenomi Inc. | Sarah B. Noonberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 57,763 | 100,374 | - | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Sarah Noonberg B. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 20,900 | 20,900 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 4,600 | 11,800 (0%) | 0% | 0 | Common Stock | |
| Neurogene Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 15,400 | 15,400 | - | - | Stock Option (Right to Buy) | |
| Neoleukin Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 32,400 | 32,400 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2023 | 7,200 | 7,200 (0%) | 0% | 0 | Common Stock | |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2022 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Neoleukin Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2021 | 18,000 | 18,000 | - | - | Stock Option (right to buy) | |
| Neoleukin Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2021 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 4,700 | 7,300 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 6.98 per share. | 10 Feb 2021 | 4,700 | 4,700 (0%) | 0% | 7.0 | 32,806 | Common Stock |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Sale of securities on an exchange or to another person at price $ 25.42 per share. | 10 Feb 2021 | 4,300 | 400 (0%) | 0% | 25.4 | 109,306 | Common Stock |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Sale of securities on an exchange or to another person at price $ 25.09 per share. | 10 Feb 2021 | 3,700 | 0 (0%) | 0% | 25.1 | 92,833 | Common Stock |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Grant, award, or other acquisition of securities at price $ 6.98 per share. | 10 Feb 2021 | 3,700 | 3,700 (0%) | 0% | 7.0 | 25,826 | Common Stock |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2021 | 3,700 | 3,600 | - | - | Stock Option (right to buy) | |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | Director | Sale of securities on an exchange or to another person at price $ 26.04 per share. | 10 Feb 2021 | 400 | 0 (0%) | 0% | 26.0 | 10,416 | Common Stock |
| Protagonist Therapeutics Inc | Sarah B. Noonberg | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2020 | 15,000 | 15,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges